MedTrace Logo

The Mass Balance Study of [14C]JT001

NCT05802810 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-06-22

No results posted yet for this study

Summary

This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of \[14C\]JT001, the data of human radioactive excretion rate and the main excretion pathway will be obtained. The main metabolites ,metabolic pathways and elimination pathways of JT001 will be identified.

Conditions

  • Healthy Subjects

Interventions

DRUG

[14C]JT001

Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally.

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • Shanghai Vinnerna Biosciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-18
Primary Completion
2023-09-27
Completion
2023-09-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05802810 on ClinicalTrials.gov